# Higher Dose of Ramipril Versus Addition of Telmisartan-Ramipril in Hypertension and Diabetes

> **NCT00208221** · PHASE3 · TERMINATED · sponsor: **Institut de Recherches Cliniques de Montreal** · enrollment: 50 (estimated)

## Conditions studied

- Hypertension
- Type 2 Diabetes
- Albuminuria

## Interventions

- **DRUG:** ramipril
- **DRUG:** ramipril-telmisartan

## Key facts

- **NCT ID:** NCT00208221
- **Lead sponsor:** Institut de Recherches Cliniques de Montreal
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-08
- **Primary completion:** —
- **Final completion:** 2007-06
- **Target enrollment:** 50 (ESTIMATED)
- **Why stopped:** Not enough recruitment
- **Last updated:** 2007-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00208221

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00208221, "Higher Dose of Ramipril Versus Addition of Telmisartan-Ramipril in Hypertension and Diabetes". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00208221. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*